Earnings Call · Q4 FY2021·2022-02-23

Q4 21EPS +33.33%·Rev n/aQ3 21EPS -22.22%·Rev n/aQ2 21EPS +54.55%·Rev n/aQ1 21EPS +7.14%·Rev n/a⚠ consensus missing

Vanda Pharmaceuticals Inc. VNDA

Kevin Moran — Chief Financial Officer

Mihael Polymeropoulos — Chief Executive Officer

Gunther Birznieks — Role not explicitly stated, likely a senior executive or medical affairs leader

Thomas Abell — Professor of Medicine, Gastroenterology Expert

Timothy Williams — Role not explicitly stated, likely a senior executive or commercial leader

−2.6%1d on move date−4.1% vs SPY3d−13.1%5d−14.8%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more VNDA calls or request research access.

More VNDA calls Browse calls Request research access